Clinical trial subject death triggers safety concerns: Cancer drug developer Erasca's stock price slashed in half, plunging 48% in a single day.

Notice that Erasca (ERAS.US) stock price plunged 48% on Tuesday, after the cancer drug developer reported that a patient died following their exit from a clinical trial, with the patient experiencing severe treatment-related side effects. The patient, a 66-year-old male, was sent to the emergency room with severe lung inflammation about a month after starting the company's therapy. He later died after stopping the treatment. This information was disclosed as the company announced early-stage clinical trial data for its experimental therapies targeting pancreatic and lung cancer. The company had previously stated that the therapy had good overall tolerability, with mostly low-grade side effects. This is the largest drop in the company's stock price since its listing in 2021. Representatives from Erasca did not immediately respond to requests for comment. HC Wainwright analyst Andres Y. Maldonado wrote in a report to clients, "While this may be an isolated incident in a complex patient case, it contradicts previous good safety profiles and raises questions about attribution and reporting consistency." This news marks the second setback for the drug developer in two consecutive days. On Monday, Erasca received a cease and desist letter from competitor Revolution Medicines Inc. (RVMD.US), accusing Erasca's cancer therapy of containing certain ingredients claimed by a patent held by Revolution Medicines. Erasca's stock price had already dropped 11% on Monday. Maldonado added and maintained a "buy" rating on Erasca, saying, "We expect the stock to face pressure in the short term until safety characteristics evolve and the litigation trajectory gains more clarity." Following Erasca's setback, Revolution Medicines' stock price rose 10% on Tuesday. Since announcing late-stage trial results earlier this month showing improved survival rates for its therapy targeting aggressive pancreatic cancer, the company's stock has been on the rise. TD Cowen analyst Marc Frahm wrote in a report that Erasca's safety reporting raises many questions. He continues to view Revolution Medicines as a "leader" in the field and reiterated a "buy" rating on the company.